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DIFFERENCES IN THE RESISTANCE OF HUMAN PLASMAS
TO STAPHYLOCOAGULASE*
MORRIS TAGER AND HARRIET B. HALES
Several observers have reported that plasmas differ in their sus-
ceptibility to staphylocoagulase. Chapman' tested 81 fresh human blood
samples with a ten-hour staphylococcus culture, and noted that at two
hours firm clots had formed with 35, partial clots with 25, while
21 bloods remained unclotted. The suggestion that such variation in
human plasmas may be due to the activity of "inhibitors" has received
support from the observation that slightly diluted plasmas may be
clotted more rapidly than are the undiluted samples. Fisher' and
Cruikshank4 therefore advocated the use of plasma diluted 1:10 for
routine coagulase testing. Chapman2 and his associates, working with
rabbit plasma, recommend a dilution of 1:4, but found higher dilu-
tionsunsatisfactory. However, no attemptwasmadeto restorefibrinogen
tothedilutedplasma. LominskiandRoberts' approached theproblem by
titrating serum for the limiting dilution which would inhibit the
clotting of plasma by coagulase. Of 348 sera, 212 contained inhibitory
substances. On the other hand, 104 plasmas subjected to the same
test only rarely inhibited coagulation, and then only in the undiluted
state. The authors explain this difference in the behavior of serum and
plasma on a greater affinity of coagulase for fibrinogen than for the
inhibitory substance. Smith and Hale,8 in a test of 40 human plasmas
noted one which failed to clot with viable staphylococci, and gave a
low titer with a cell-free filtrate. They suggest-
' that this is due not so
much to inhibitory substances, as to a lack of the "activator" in the
plasma.
Recent studies have reopened the controversial problem of the
antigenicity of coagulase. It has been shown that following hyper-
immunization with concentrated purified coagulase, rabbit plasmas be-
come more resistant to the action of coagulase, that an enhanced serum
neutralization develops, and that complement-fixing and collodion
particle agglutinating bodies appear.3 The specificity of the inhibition
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gained support from a combined collodion particle and neutralization
test, in which the neutralizing bodies were specifically adsorbed by the
coagulase-coated collodion particles. Rammelkamp7 reported that
monkeys develop a rising titer of anticoagulase following immunization
with cell-free coagulase, and that human acute and convalescent phase
sera of patients with staphylococcal infection showed an increase in the
anticoagulase titer in later blood samples.
Earlier observations on coagulase inhibition have been carried out
with living cultures, or at best with relatively weak cell-free filtrates.
By the use of a standardized quantitative technique utilizing a relatively
potent cell-free coagulase preparation, the present study attempts to
define the base line for the susceptibility of human plasma to this agent,
and to indicate whether the observed variations may be ascribed entirely
to one or another of the proposed mechanisms of interference.
Materials andmethods
Human plasma. Plasma was obtained from the blood bank, from prospective
blood donors, and from clinic patients.* The blood bank plasma was prepared
with an anti-coagulant of citrate-citric acid glucose solution, 10 per cent by
volume. The other blood samples were drawn into a 0.25 per cent solution of
sodium citrate, also 10 per cent by volume. The clinic and donor bloods were
titrated immediately, while the blood bank material varied in age from 24 hours
to 4 weeks. Clotted samples were avoided. Such blood as was released before the
expiration date was regarded as unsuitable for clinical use, because of positive
serology, or, rarely, was returned from the wards because of transfusion re-
action. Preliminary studies established that the inhibitory activity of the blood
bank plasma was not due to age or to citrate excess. All red cells were removed
by centrifugation.
Coagulase. In all tests, the same stable cell-free coagulase solution was used.
It was preserved with 1:10,000 merthiolate and was kept in the refrigerator at
all times. When this stock solution was tested against a "non-inhibitory" plasma,
coagulation occurred at 370 C. in 24 hours with a coagulase dilution of 1:5120 to
1:10,240. The titration technique, previously detailed,10 consisted essentially
in making serial two-fold dilutions of coagulase in two per cent peptone-saline
in a volume of 0.5 ml., adding 0.5 ml. of undiluted plasma, and maintaining a
final merthiolate concentration of 1:10,000. The progress of the reaction was
observed at various time intervals up to 24 hours in a water-bath at 370 C.
The coagulase-feacting factor. The titration technique has been described
elsewhere."
Serum neutralization test. The Lominski and Roberts6 methods were followed.
Collodion particle agglutination. Cavelti's' methods, slightly modified,'8
wereused.
I The authors are greatly indebted to Dr. William E. Bloomer, Dr. Maurice J.
Strauss, and Miss Juliet Drabkin for cooperation in the securing of plasma.
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Results
In Table 1 are summarized the reactions of 307 human plasmas
titrated against serial dilutions of the same coagulase preparation.
Since preliminary studies failed to show any significant changes in
plasma resistance on standing in the ice-box for well over 30 days, the
data pertaining to the blood bank plasma were not treated separately
from those of the fresh samples. The subgrouping of the plasmas in-
dicating the degrees of inhibition was arbitrary. It is evident that the
majority of specimens examined showed resistance to coagulase; indeed,
eight samples failed to clot with the most concentrated dilution of
coagulase tested (1:20), while only 6.84 per cent of the plasmas may
be regarded as essentially non-resistant.
Table 1
THE REACTION OF HUMAN PLASMAS WITH COAGULASE
Coag. titer 0 10 20 30 40 60 80 100 120 140 160 200 240 280 320 400
N1r. of plasmas 867 8 10 8 1425 4 12 5 11 0 6 3
Coag. titer 480 560 640 800 960 1120 1280 1600 1920 2240 2560 3200
Nr. of plasmas 18 1 8 7 7 2 17 9 20 5 20 20
Coag. titer 3g40 4480 5120 7680 8960 10,240
Nr. of plasmas 30 13 19 1 1 0
Summary: Per cent distribution of resistant plasmas
Degree of
Group Inhibition Number of Plasmas Per cent of total
1. 3+ (0-1:80) 61 19.86
2. 2+ (1:100-1:640) 75 24.42
3. 1+ (1:800-1:4480) 150 48.85
4. 0 (1:5120-1:10,240) 21 6.84
Total 307 99.97
Since Lominski and Roberts found that 212 of 348 human sera
inhibitthecoagulase-plasma reaction, an attemptwas made to determine
whether any parallelism exists between their procedure and the one
adopted in the present study. Thirteen plasmas were accordingly re-
calcified, and titrations were carried out by both methods (Table 2).
It will be noted that a general parallelism exists in the results ob-
tained by the two techniques. It should be pointed out, however, that
unless the optimal dilution of coagulase is used, erroneous results may
beobtained, since an excess ofcoagulase may mask serum neutralization.
Also, other than quantitative considerations may be involved, since an
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immune rabbit serum, seemingly of comparable activity to an inhibitory
human plasma when tested as plasma by the coagulase dilution method,
proved far more effective than the human sample when used in a
serum neutralization test.
Table 2
CORRELATION BETWEEN PLASMA INHIBITION TESTS AND SERUM NEUTRALIZATION.
Degree of plasma inhibition* Degree of serum neutralization*
1 0 ............................................................0
0 ...........................................................
2+ ............................................................ 1+
4+ ............................................................ 4+
1+ .....................................................0.......
0
2+ ............................................................ 2+
2+ ............................................................ 2+
1+ ............................................................
10 0 ...........................................................
11 3+ ............................................................ 2+
12 3+ ............................................................ 3+
13 1+ ............................................................
* maximum inhibition, 4+; no inhibition, 0
In view of the suggestion that the resistance of human plasma to
coagulase might represent a deficiency8'9 of "activator" or coagulase-
reactingfactor, a series of 100 plasmas, varyingwidely in their resistance
to coagulase, were also tested for reacting-factor content. The technique,
previously detailed,11 consisted essentially in simultaneously titrating
serial coagulase dilutions against ten-fold plasma dilutions, with the
appropriate addition of bovine fibrinogen beyond the undiluted plasma
level. Thecoagulase-fibrinogen andplasma-fibrinogen controls remained
negative. The same stable coagulase preparation was used for all tests.
In Table 3 the findings are illustrated by 35 unselected plasmas, all ob-
tained from normal adult blood donors. It is evident that the resistance
of the plasma at the undiluted level bore no relationship to the
coagulase-reacting factor content of the plasma. Indeed, this factor re-
mained remarkably constant, the end points falling within one dilution,
between 1:10,000 and 1:100,000.
Following the experimental immunization of rabbits with
coagulase,13 agglutinins for coagulase-coated collodion particles may
appear. This phenomenon made feasible the demonstration of the
antibody nature of the inhibitory substances of the blood of im-
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Table 3
THE RELATION OF CONTENT OF COAGULASE-REACTING FACTOR TO PLASMA
RESISTANCE TO COAGULASE.
Nr. of plasma Plasma Resistance to Coag.* C.R.F. content/
1 5120 i05
2 5120 105
3 5120 105
4 5120 105
5 4480 105
6 3840 104
7 3200 105
8 3200 105
9 3200 105trace
10 2560 105
11 2560 105
12 2560 105trace
13 2560 105trace
14 980 104
15 480 105
16 320 105trace
17 160 105
18 320 105trace
19 160 105
20 160 105
21 160 105trace
22 160 104
23 160 104
24 100 105
25 80 105
26 80 105
27 80 105trace
28 60 105
29 60 105trace
30 40 105
31 40 105
32 40 105trace
33 40 l05trace
34 30 104
35 10 105trace
Reciprocal of coagulase dilution clotting undiluted plasma in 24 hours at 370 C.
tReciprocal of plasma dilution clotting with the addition of coagulase and bovine
fibrinogen, 280 mg. per cent, in 24 hours at 370 C. Plasma-fibrinogen and coagulase-
fibrinogen controls: no clot formation.
munized animals by permitting combined tests for agglutination and
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whether inhibitory human blood behaves similarly. Since Cavelti has
reported that older human blood may cause non-specific agglutination,
the study was limited to freshly drawn material. Fifty sera were tested
without knowledge of their plasma resistance titers. None of these
showed any collodion particle agglutination. Forty additional fresh
specimens were obtained from the dermatology clinic; of these, 10
were highly inhibitory with titers of 0 to 1:80, and 9 moderately
resistant, with titers of 1:100 to 1:640. Only one of these patients
was acutely ill: a young man with reactivated lupus vulgaris, with
superimposed secondary infection and fever. His plasma was inhibitory,
coagulase-coated collodion particles were agglutinated by a serum dilu-
tion of 1:8. None of the other specimens caused any collodion particle
agglutination.
Discussion
As has been previously noted, Lominski and Roberts reported that
only a few of 104 plasmas tested for inhibitory activity were positive,
while 212 of 348 sera were inhibitory. In the present study, however,
marked differences in the resistance of human plasma were readily
demonstrated by a technique of coagulase dilutions reacting with a
constant undiluted plasma, except for ten per cent anticoagulant.
Indeed, some 93 per cent of adult human plasmas were more or less
inhibitory. Some of these proved completely refractory, in spite of
adequatecontentofthebloodcomponents which enterintophysiological
clotting, although a more potent coagulase would undoubtedly have
given a measurable end-point. In spite of a general parallelism between
the two techniques, it has been noted that an "immune" rabbit serum
was far more effective in the Lominski test than was a human serum
prepared from an inhibitory plasma of the same activity as the rabbit
plasma. One cannot therefore be entirely certain that the human
plasma resistance is mediated by the same agent as that operating in
the development of resistance in an immunized rabbit.
The problem of antibody versus non-specific inhibitors, therefore
continues to be difficult to resolve on the basis of available evidence.
Efforts at direct identification of the inhibitors of human plasma with
antibodies by a collodion particle agglutination technique were not
possible, since, with one exception, no agglutination took place. Al-
though recent work has brought support to the view that coagulase
may be antigenic,7 l3 the operation of other inhibitory mechanisms,
such as ascorbic acid and proteolytic enzymes, is equally well estab-
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lished."2 Onemay,however, withreasonablecertaintyruleoutsignificant
fluctuations of the "activator" or coagulase-reacting factor as being
responsible for the plasma resistance which has been observed. This by
no means implies that under some pathological conditions variations
in the reacting factor may not occur, and indeed that these may not
prove of clinical significance.
The present observations point to the desirability of further studies
which may shed some added light on the mechanism of the plasma
resistance. Thus, it would be of special interest to extend the examina-
tion ofplasmas to various age groups, including particularly infants and
children, to note whether the development of coagulase resistance
-parallels the well-defined pattern set by other antibodies, such as that of
diphtheria antitoxin. A more direct approach would be a study of
plasma resistance in relation to staphylococcal infection. Unfortunately,
the few observations which were made on this phase of the problem
proved inconclusive. The studies of Rammelkamp,7 however, suggest
that serum inhibition of coagulase rises in the wake ofstaphylococcal in-
fection in man and in the monkey.
Summary
The resistance of human plasma to staphylocoagulase was studied
by a test in which serial dilutions of a cell-free coagulase preparation
were reacted with undiluted plasma.
Of 307 adult human plasmas, about 7 per cent were non-inhibitory,
reacting with a coagulase dilution of 1:5120 to 1:10,240. Ninety-three
per cent of the plasmas showed evidence of resistance to coagulase,
ranging from complete refractoriness to varying degrees of inhibition.
The possible mechanisms of this resistance are discussed.
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